Investigating how prostate cancer cells change and become resistant to treatment
Official title: Studies on Lineage Plasticity in Prostate Cancer
Funded at Sloan-Kettering Inst Can Research · NIH-10877990 · Data updated 2026-11-12
This study is looking at how prostate cancer cells can change and become resistant to treatments, and it's for patients with advanced prostate cancer who want to know if there are ways to make their current therapies work better again.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | July 1, 2023 |
| Project end | June 30, 2028 |
| Funding year | 2024 |
| Award (this year) | $277,685 |
| NIH project number | 5K08CA282978-02 |
| Project ID | NIH-10877990 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with castrate-resistant prostate cancer who have experienced treatment failure.
✕Less likely to help
Patients with early-stage prostate cancer or those who have not yet undergone treatment may not benefit from this research.
What this research studies
This research focuses on understanding how prostate cancer cells can change their characteristics, leading to treatment resistance. The team will explore the molecular mechanisms behind this process, particularly how certain signaling pathways contribute to these changes. By using advanced techniques like CRISPR and ATAC sequencing, they aim to identify potential targets for reversing this resistance. The ultimate goal is to find ways to restore sensitivity to existing therapies for patients with advanced prostate cancer.
Why it matters
Potential benefit: If successful, this research could lead to new treatment strategies that help prostate cancer patients respond better to therapies.
How similar studies have gone: Previous research has shown promising results in reversing treatment resistance in other cancers using similar molecular targeting approaches.
Where this research is happening
-
Sloan-Kettering Inst Can Research
New York, United States Active
Researchers
- Principal investigator: Zaidi, Samir — Sloan-Kettering Inst Can Research
- Study coordinator: Zaidi, Samir
Related research
Other NIH-funded projects on the same topics.
-
Cardiovascular risk planning and reduction for men with prostate cancer
A program to better predict and reduce heart disease risk in men treated for prostate cancer, especially older patients.
-
Effects of ADT on motivation and emotion in prostate cancer patients
This project looks at how androgen deprivation therapy may affect motivation and mood over time in men with prostate cancer.
-
Causal Protein Markers to Understand and Predict Prostate Cancer Risk in Africans and Europeans
A cancer research project looking at proteins linked to prostate cancer to better understand why it happens and how risk differs between African and European populations.
-
Ethical multimodal AI platform to improve prostate cancer detection with ultrasound
A patient-friendly AI system uses ultrasound and MRI information to help doctors better find prostate cancer, aiming to improve accuracy and access.
-
Characterizing epigenetic targets in prostate cancer to help AR-driven cancer
A research project at MD Anderson aims to understand how epigenetic factors shape androgen receptor signaling in prostate cancer to find new ways to treat resistant forms of the disease.
-
AR and RNA-binding in prostate cancer resistance
A cancer research grant exploring how the androgen receptor’s interaction with RNA may drive treatment resistance in prostate cancer, with potential to guide new therapies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.